Dr. Michael Bishop presents results from a phase 1 study of anito-cel, an anti-BCMA CAR-T cell therapy. The therapy shows excellent long-term efficacy and tolerability, with minimal incidence of severe cytokine release syndrome and neurologic toxicities, and it is currently being investigated in an ongoing phase 2 trial at the University of Chicago.

Link to ASH playlist: [ Ссылка ]

ASH Abstract: Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Efficacy and Safety with 34-Month Median Follow-up
#ASH24 #Myeloma #mmsm

Follow HealthTree:
[ Ссылка ]
twitter.com/healthtreeformm
facebook.com/healthtreeformultiplemyeloma
instragram.com/healthtreeformultiplemyeloma

свернуть